S

Cassava Sciences
D

SAVA

26.500
USD
-5.70
(-17.70%)
Market Closed
Volume
158,600
EPS
-3
Div Yield
-
P/E
-19
Market Cap
1,274,927,588
OverviewSignalsIdeasNews
Related Instruments
    A
    ACIU
    -0.34000
    (-9.58%)
    3.21000 USD
    A
    AGIO
    -1.645
    (-2.97%)
    53.810 USD
    A
    ANVS
    -0.09500
    (-1.37%)
    6.83500 USD
    A
    AVXL
    -0.57500
    (-7.17%)
    7.45000 USD
    BIIB
    BIIB
    -4.840
    (-2.94%)
    160.000 USD
    C
    CRBP
    -0.950
    (-5.41%)
    16.610 USD
    C
    CTSO
    -0.05990
    (-6.24%)
    0.90000 USD
    S
    SAVA
    0.700
    (2.68%)
    26.850 USD
    More
News

Title: Cassava Sciences

Sector: Healthcare
Industry: Biotechnology
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.